The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway by Bailly, A. et al.
                                                              
University of Dundee
The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53
through the ribosomal-Mdm2 pathway
Bailly, A.; Perrin, A.; Bou Malhab, L. J.; Pion, E.; Larance, M.; Nagala, M.; Smith, P.;
O'Donohue, M.-F.; Gleizes, P.-E.; Zomerdijk, Josephus; Lamond, A. I.; Xirodimas, D. P.
Published in:
Oncogene
DOI:
10.1038/onc.2015.104
Publication date:
2016
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Bailly, A., Perrin, A., Bou Malhab, L. J., Pion, E., Larance, M., Nagala, M., ... Xirodimas, D. P. (2016). The
NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2
pathway. Oncogene, 35(4), 415-426. DOI: 10.1038/onc.2015.104
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
 1 
The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates 
p53 through the ribosomal-Mdm2 pathway 
Aymeric Bailly1, Aurelien Perrin1#, Lara Bou Malhab1#, Emmanuelle Pion1, Mark 
Larance2, Manjula Nagala2, Peter Smith3, Marie-Françoise O'Donohue4, Pierre-
Emmanuel Gleizes4, Joost Zomerdijk2, Angus I. Lamond2 and Dimitris P. 
Xirodimas1* 
1Centre de Recherche de Biochimie Macromoléculaire - UMR 5237, CNRS, Route de 
Mende 34 293, Montpellier, Cedex 5, France 
2Centre for Gene Regulation and Expression, College of Life Sciences, University of 
Dundee, Dow Street, Dundee, DD1 5EH, Scotland/UK 
3Millennium Pharmaceuticals Inc., 40 Landsdowne Street, Cambridge, MA 02139, 
USA 
4Laboratoire de Biologie Moléculaire Eucaryote, UMR CNRS 5099, Bâtiment IBCG, 
118 route de Narbonne, 31062  Toulouse Cedex 9, France 
# These authors contributed equally to this work 
 
*corresponding author 
tel: +44 1382 386303 
fax: +44 1382 386375 
               email: dimitris.xirodimas@crbm.cnrs.fr 
                
 
Running title: MLN4924 targets the nucleolus 
 
 2 
Abstract  
The ubiquitin like molecule NEDD8 is essential for viability, growth and 
development and is a potential target for therapeutic intervention. We found that the 
small molecule inhibitor of NEDDylation MLN4924 alters the morphology and 
increases the surface size of the nucleolus in human and in germline cells of C. 
elegans in the absence of nucleolar fragmentation. SILAC proteomics and monitoring 
of rRNA production, processing and ribosome profiling shows that MLN4924 
changes the composition of the nucleolar proteome but does not inhibit RNA Pol I 
transcription. Further analysis demonstrates that MLN4924 activates the p53 tumour 
suppressor through the RPL11/RPL5-Mdm2 pathway, with characteristics of 
nucleolar stress. The study identifies the nucleolus as a target of inhibitors of 
NEDDylation and provides a mechanism for p53 activation upon NEDD8 inhibition. 
It also indicates that targeting the nucleolar proteome without affecting nucleolar 
transcription initiates the required signalling events for the control of cell cycle 
regulators. 
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Introduction 
The NEDD8 ubiquitin like molecule is vital for a range of processes including cell 
viability, growth and development. Covalent modification of NEDD8 is initiated by 
the processing of the C-terminal tail to expose a di-glycine motif. This 
mature/processed form of NEDD8 is activated by an E1 activating enzyme (known as 
APPBP1/Uba3 or NAE) and is transferred to substrate proteins through the action of 
E2 conjugating enzymes and E3-ligase 1, 2, 3, 4. Several targets for NEDD8 have been 
identified but the most well-characterised substrate is the cullin family of proteins 5, 6. 
Cullins are scaffold components for RING E3-ubiquitin ligases, called CRL (Cullin 
Ring Ligases). NEDDylation of cullins stimulates the activity of the E3-ligase, 
resulting in increased degradation of substrate proteins through the Ubiquitin 
Proteasome System (UPS) 7, 8. It is estimated that CRLs have several hundred 
substrates, including cell cycle regulators, components of the DNA replication 
machinery and mediators of cellular stress, such as hypoxia and oxidative stress 7, 9. 
Therefore, a well-described function of NEDD8 is to promote protein degradation 
through UPS. This knowledge combined with the fact that the inhibitor of the 
proteasome, bortezomib (Velcade®), is used for the treatment of various types of 
myeloma and lymphoma, prompted development of specific inhibitors of the NEDD8 
machinery 4, 10. MLN4924 is a small molecule that specifically inhibits the NEDD8 
pathway 11, 12. Treatment of tumour cells with MLN4924 can induce apoptosis, and in 
vivo MLN4924 shows anti-tumour activity in mice harbouring human xenografts for 
solid and hematologic tumours 11. These encouraging preclinical studies with 
MLN4924 provided the rationale for early phase clinical studies 1, 4. Therefore, 
elucidation of pathways controlled by NEDD8 becomes increasingly important. 
Recent studies showed that inhibition of NEDDylation by MLN4924 activates the p53 
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tumour suppressor and that the p53 pathway is relevant for the biological response to 
MLN4924 treatment 13, 14. Interestingly, MLN4924-induced apoptosis is increased 
upon knockdown of p53 in tumour cell lines containing wild type p53, suggesting that 
p53 activation may protect cells against MLN4924 13. However, the mechanism for 
the MLN4924-induced p53 activation remains elusive. 
The nucleolus is the subnuclear structure at the centre of ribosomal RNA (rRNA) 
transcription and ribosome subunit production, and is thus essential for protein 
synthesis and cell growth 15, 16, 17. What is also evident is that the nucleolus is not a 
static subnuclear structure but responds to a great variety of cellular stresses. DNA 
damage induced by ionizing radiation, UV or chemotherapeutic drugs, inhibition of 
RNA Pol I transcription by nutrient starvation or Actinomycin D (ActD), proteasome 
inhibition and viral infection, can all change nucleolar structure and alter the nucleolar 
proteome 18, 19, 20, 21, 22, 23.  
Induction of nucleolar stress elicits signalling events with important biological 
consequences for cell cycle progression. For example, the p53 tumour suppressor 
responds to the majority of known nucleolar stressors, with the best characterized 
being the inhibition of RNA Pol I transcription 24. Low doses of ActD specifically 
inhibit RNA Pol I and thus the production of rRNA in the nucleolus 25. Under these 
conditions, several RPs have been reported to block Mdm2 E3-ligase activity towards 
p53 through direct binding to Mdm2. In particular, for RPL11 and RPL5, a co-
operation between the 2 RPs and 5S rRNA enhances Mdm2 inhibition under 
ribosomal stress conditions 26, 27. This causes p53 stabilisation, activation of the p53 
response and cell cycle arrest 28, 29, 30 ,31.  
We found that inhibition of NEDDylation by MLN4924 alters the morphology and 
increases the surface size of the nucleolus in the absence of nucleolar fragmentation 
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both in human cells and in C. elegans germline cells. Combination of SILAC 
quantitative proteomics, rRNA production/processing and ribosome profiling show 
that in contrast to the established nucleolar stressor ActD, MLN4924 alters the 
nucleolar proteome but does not affect RNA Pol I transcription. Further analysis 
shows that MLN4924 activates the p53 pathway through the RP-Mdm2 module with 
characteristics of nucleolar stress. This study reveals that MLN4924 causes activation 
of key tumour suppressor pathways through the nucleolus. Furthermore, the data 
support a conserved role for NEDDylation as a regulator of nucleolar signaling. As 
MLN4924 is currently being tested in clinical trials, this study identifies the nucleolus 
as a target for the action of a potential novel chemotherapeutic drug. 
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Results 
MLN4924 increases the surface size of the nucleolus in human cells and in C. 
elegans germline cells 
Inhibition of NEDDylation by MLN4924 produces diverse biological effects mainly 
through inhibition of CRL function. We observed that treatment with MLN4924 
altered the morphology of the nucleolus without detectable nucleolar fragmentation 
(Fig. 1A). To investigate in more detail the effect of MLN4924 on nucleolar 
organisation, we monitored the effect of MLN4924 on the localization of nucleolar 
proteins that reside within distinct areas in the nucleolus. U2OS cells were either 
untreated or treated with MLN4924 and the localization of nucleolin and fibrillarin 
(dense fibrillar component) and B23/nucleophosmin (granular component) was 
monitored. MLN4924 has no effect on the localization of any of the tested nucleolar 
proteins, confirming that MLN4924 affects the morphology but not the integrity of 
the nucleolus (Fig. 1B). We also observed that the surface size of the nucleolus is 
altered in the MLN4924 treated compared to untreated cells. We designed an 
experiment, similar to that described by Nicholas Baker 32, to quantify changes in the 
nucleolar surface size under different conditions. We performed fibrillarin and DAPI 
staining to define the nucleolus and the nucleus area respectively using the same 
cross-sectional areas. To provide a measure of nucleolar and nuclear surface area, we 
determined the number of pixels by defining the minimal and maximal thresholds 
independent of labelling intensity, as described in supplementary information. The 
ratio of the nucleolar to nuclear area determines the relative changes in nucleolar size 
under different conditions. MLN4924 caused a significant increase in nucleolar 
surface area compared to control cells (Fig. 1C, D). As controls we used the 
chemotherapeutic drugs ActD and doxorubicin that cause nucleolar segregation (Fig. 
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1E). Protein NEDDylation is a highly conserved post-translational modification. We 
used C. elegans as a model organism to determine the conservation of our 
observations on the effect of NEDD8 inhibition on nucleolar morphology and to also 
establish the physiology of our observations at organism level. We treated C. elegans 
with MLN4924 and performed similar analysis on the surface area of the nucleolus to 
that performed in human cells 33. We focused on germline cells as they rapidly 
proliferate and contain relatively large nucleoli that can be easily monitored and 
studied. Animals were either untreated or treated with MLN4924 and germline cells 
were dissected and stained for fibrillarin and with DAP1 to determine the nucleolar 
and nuclear area as before. We found that similarly to what is observed in human cells 
MLN4924 caused a significant increase in nucleolar surface area (Fig. 2A, B). Similar 
results were obtained with siRNA against the C. elegans NEDD8 (NED-8) (Fig. 2A, 
B). Application of genotoxic treatments including UV, ActD, or doxorubicin caused 
the formation of either distinct nucleolar fragments (UV) or sub-fragmentation 
(segregation) within the defined nucleolar area (ActD and doxorubicin) (Fig. 2C). The 
above data identify a role for NEDD8 in controlling nucleolar morphology and 
surface area, which is conserved between humans and C. elegans.    
MLN4924 activates p53 through the RP-Mdm2 pathway 
Changes in the nucleolar morphology usually reflect changes in the nucleolar 
function, which are detected by multiple cell cycle regulators 23. The p53 tumour 
suppressor is a sensitive sensor of nucleolar misfunction. Ribosomal proteins are key 
players in transmitting defects in nucleolar function to p53 through inhibition of the 
Mdm2 E3-ligase 30. We hypothesized that if p53 activation by MLN4924 is due to the 
observed changes in nucleolar morphology, it should depend on the RP-Mdm2 
signalling pathway. Further evidence to support this hypothesis derive from previous 
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studies that showed that inhibition of NEDDylation of RPL11 participates in p53 
activation upon nucleolar stress 34.  
MCF7 cells, which contain wild type endogenous p53 were treated with increasing 
doses of MLN4924. As expected, MLN4924 decreased Cullin-1 NEDDylation (Fig. 
3A). MLN4924 also increased p53 levels in a dose-dependent manner and the 
expression of p53 regulated genes 35, consistent with previous studies and with the 
notion that inhibition of NEDDylation causes p53 activation (Fig. 3A). Similar effects 
of MLN4924 were observed in other p53 positive cell lines, including U2OS, 
HCT116 and A375 (data not shown).  
We next determined the effect of MLN4924 on L11 NEDDylation. H1299 cells were 
transiently transfected with plasmid vectors encoding Flag-L11 and His6-NEDD8. 
His6-NEDDylated proteins were isolated by Ni-agarose chromatography and blotted 
for Flag-L11. MLN4924 decreased RPL11 NEDDylation (pull-down) relative to total 
levels of RPL11 (whole extracts) (Fig. 3B). Consistent with the notion that prolonged 
inhibition of NEDDylation also leads to RPL11 degradation, MLN4924 decreased the 
total levels of RPL11 (Fig. 3B) 34, 36. The nucleolus is a dynamic structure, and it has 
been established that nucleolar disruption correlates with altered mobility kinetics of 
many nucleolar proteins 36, 37, 38. We used live cell imaging and Fluorescence 
Recovery After Photobleaching (FRAP) to determine the effect of MLN4924 on the 
mobility of RPL11. We used H1299 cells stably expressing RPL11-EGFP that were 
either untreated or treated with MLN4924. As control we used Actinomycin D, which 
is known to affect the mobility of ribosomal proteins 36, 37, 38, 39. By measuring in real 
time the recovery of the EGFP signal in the nucleolus after bleaching, we found that 
both MLN4924 and ActD decreased the mobility of RPL11-EGFP (Fig. 3C).  
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The data suggest that MLN4924 may impact on p53 function through mechanisms 
involving RPL11. To determine the role of RPL11 in p53 stabilisation by MLN4924 
we transfected MCF7 cells either with control or RPL11-specific siRNAs and treated 
with either MLN4924, or with low doses of ActD. MLN4924 causes p53 stabilisation 
and induction of the well-described p53 regulated gene, Mdm2 (Fig. 4A left, 4B top 
panel) 35. However, knockdown of RPL11 reduced p53 stabilisation and 
transcriptional activation by MLN4924, similar to that observed with ActD (Fig. 4A, 
B). The defects in p53 stabilisation by MLN4924 were observed with four separate 
siRNAs, targeting different parts of the RPL11 mRNA sequence (Fig. 4C). Therefore, 
RPL11 is required for p53 activation by MLN4924, similar to what is observed by 
ActD-induced nucleolar stress 40, 41. 
The Mdm2 E3 ligase is an important p53 regulator, and is known to play a critical 
role in p53 activation upon nucleolar stress 30, 42. Direct binding of RPs to Mdm2 
blocks Mdm2-mediated p53 degradation allowing p53 accumulation 43. For RPL11 
and RPL5 genetic studies demonstrated the importance of their binding to Mdm2 in 
p53 nucleolar signaling. Transgenic mice expressing a single amino acid mutant of 
Mdm2 (C305F) that cannot interact with RPL11 and RPL5 were shown to be resistant 
to nucleolar stress induced by ActD 44. To test whether p53 activation by MLN4924 
depends on RPL11/RPL5-Mdm2 interaction we used MEFs that express either wild 
type Mdm2 or the Mdm2 C305F mutant. As reported, low doses of ActD cause p53 
stabilisation in the wild type MEFs, but not in the Mdm2 C305F mutant MEFs (Fig. 
4D). MLN4924 stabilised p53 in wild type MEFs, although to a much lesser extent 
than in other cell lines tested. However, in the Mdm2 mutant MEFs, MLN4924 did 
not cause any detectable p53 stabilization (Fig. 4D, right panel) even though Cullin 
NEDDylation is completely blocked. Consistent with the above data, knockdown of 
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RPL5 also compromises MLN4924 induced p53 stabilisation (supplementary 
information S1). In combination, the above data strongly suggest that MLN4924 
causes p53 stabilisation through the nucleolus involving the RP-Mdm2 pathway. We 
also tested the effect of MLN4924 in the activation of CEP-1, the p53 homologue in 
C. elegans, which lack both key p53 regulators Mdm2 and Mdmx. Treatment of C. 
elegans with either MLN4924 or ActD had no effect on CEP-1/p53 transcriptional 
activity (Fig. 4E) despite the clear effects on nucleolus size and morphology (Fig. 
2C). In contrast, treatment with UV causes a robust CEP-1/p53 activation (Fig. 4E). 
The data in C. elegans recapitulate the results in the transgenic Mdm2C305F mice 
where p53 is insensitive to nucleolar stress induced by ActD, but not to other forms of 
DNA damage, due to lack of Mdm2-RP binding 44. Therefore, lack of nucleolar stress 
signaling to CEP-1/p53 in C. elegans may be due to the absence of Mdm2.  
MLN4924 alters the composition of the nucleolar proteome but does not inhibit 
nucleolar transcription  
Comparison between the effects of MLN4924 and ActD within the p53 pathway 
shows several similarities: Both compounds activate p53 in RPL11/RPL5 and 
Mdm2C305F dependent manner, inhibit RPL11 NEDDylation and decrease RPL11 
nucleolar mobility. The fact that at low doses (1-5nM), ActD is relatively specific in 
blocking RNA Pol I dependent transcription raises the possibility that MLN4924 can 
elicit its effect on p53 through transcriptional inhibition in the nucleolus.  
We performed different experiments to determine the effect of MLN4924 on 
nucleolar function. We combined SILAC with mass spectrometry to provide a 
quantitative proteomic analysis of the nucleolus upon inhibition of NEDDylation 20. 
U2OS cells labeled with arginine and lysine containing either light (R0K0), medium 
(R6K4), or heavy (R10K8) stable isotopes were either untreated 14, or treated with 
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ActD (medium), or with MLN4924 (heavy), for 15hrs. Equal numbers of light, 
medium and heavy cells were mixed, fractionated and nucleoli isolated (Fig. 5A). 
Proteins from the resulting nucleolar extracts were separated by gel filtration and each 
fraction trypsin digested and analysed by mass spectrometry (supplementary 
information S2). Over 1,300 proteins were identified and quantified. Treatment with 
MLN4924 caused an increased abundance of 98 proteins and a decreased abundance 
of 21 nucleolar proteins by at least 1.3 fold relative to nucleolar proteins of untreated 
cells (Fig. 5B and supplementary information), whereas low doses of ActD, resulted 
in 95 nucleolar proteins increasing in abundance and 31 proteins decreasing, by at 
least 1.5 fold relative to nucleolar protein levels in the untreated control cells (Fig. 5B 
and supplementary information).  
Network analysis for the regulated proteins did not provide any evidence for an effect 
of MLN4924 on RNA Pol I dependent transcription. Rather, components of the RNA 
Pol II and DNA replication processes were significantly enriched in the nucleolus 
upon MLN4924 treatment. This includes elongation activators TCEB1, 2, the 
component of the core-TFIIH transcription factor GTF2H1, multiple members of the 
MCM family of DNA replication licensing factors, along with histone 
acetyltransferase complexes including MRFAP1, MORF4L2 and MORF4L1, Tip60 
and the histone de-acetylase HDAC1 (Fig. 5C, S3A, B). The nucleolar abundance of 
histone H1 and many of its variants was decreased by MLN4924 (S3A, B). Histone 
H1 is preferentially associated with the “linker” DNA between nucleosomes and is 
thought not to have a major effect on global transcription but can act as positive or 
negative gene-specific regulator of transcription in vivo 45. In contrast and as 
expected, the major targets of ActD are regulators of RNA Pol I transcriptional 
activity and rRNA processing including coilin and fibrillarin (S3C). A group of 
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proteins affected both by MLN4924 and ActD was also identified (Fig. 5D). 
Interestingly, the relative abundance of RRS1 (Ribosome biogenesis regulatory 
protein) was decreased following treatment of cells with either compound, while other 
proteins, such as PCNA (Proliferating cell nuclear antigen) and DNA replication 
licensing factors, were differentially affected, with MLN4924 increasing and ActD 
decreasing their nucleolar abundance, respectively.  The data indicate that inhibition 
of NEDDylation causes changes in the nucleolar proteome on a similar scale to the 
well-described chemotherapeutic drug ActD, but does not affect RNA Pol I function. 
We further confirmed this notion by directly monitoring the effect of MLN4924 on 
RNA Pol I activity. We used H1299 cells, which are genetically null for p53, to avoid 
the potential downstream effects of p53 activation on RNA Pol I transcription 46. 
Incorporation of 3H-uridine on nascent rRNA was monitored in H1299 cells treated 
either with low doses of ActD, or with MLN4924. As expected, ActD caused a 
dramatic inhibition of 47S rRNA production and in the appearance of the 32S, 28S 
and 18S rRNA processed forms (Fig. 5E) 25, 47. However, application of MLN4924 
did not cause any detectable changes in rRNA production (Fig. 5E). Consistently, 
analysis of pre-rRNAs by Northern blotting after MLN4924 treatment did not reveal 
any major differences for the 40S precursors (5’ITS1 probe) compared to control 
cells, while ActD treated cells were almost devoid of pre-rRNAs (Fig. 5F). To further 
investigate the potential effect of MLN4924 on ribosome subunit biogenesis, we 
analysed ribosome production using sucrose gradient ultracentrifugation. As control 
we used ActD, which impairs ribosome subunit biogenesis, mainly through inhibition 
of rRNA production 36. As expected, ActD caused a decrease in large and small 
ribosome subunits and polysome formation (Fig. 5G). MLN4924 treatment had no 
detectable effect on the polysome fraction but it caused a decrease in the ratio of 
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60S/40S subunit production (Fig. 5G). Similar defects in the 60S/40S ratio have been 
reported upon knockdown of large ribosome subunit proteins RPL7a, RPL11, RPL5, 
RPL14, RPL26, RPL35a 48, 49, 50. The combination of the data, suggest that the 
activation of p53 by MLN4924 is not due to RNA Pol I inhibition but rather due to re-
organisation of the nucleolar proteome that involves targeting RPs.  
Differential roles of RPL11 and p53 in MLN4924-induced accumulation of cells 
in S-phase and cytotoxicity 
Our studies have identified RPL11 as an important cellular factor required for the 
MLN4924 induced p53 activation. The MLN4924 induced toxicity in proliferating 
cells, is mainly due to the resulting S-phase arrest 11. We tested the effect of p53 and 
RPL11 knockdown on cell cycle progression (Fig. 6A, supplementary information 
S4) and viability (Fig. 6B) upon inhibition of NEDDylation by MLN4924. As 
expected, treatment of control siRNA transfected MCF7 cells with MLN4924 
increased the proportion of cells in S-phase with a corresponding decrease in cell 
viability (Fig. 6A, 6B). Knockdown of p53 promoted the accumulation of cells in S-
phase following MLN4924 treatment and enhanced MLN4924 toxicity (Fig. 6A, 6B). 
The opposite effect was observed upon RPL11 knockdown, which reduced both the 
MLN4924-induced accumulation of cells in S-phase and cytotoxicity (Fig. 6A, 6B). 
However, the effects of RPL11 knockdown on cell cycle and survival are p53 
independent, as simultaneous knockdown of RPL11 and p53 did not alter the effect of 
RPL11 knockdown upon MLN4924 treatment (Fig 6A, 6B). Similar results on cell 
survival were obtained when instead of MLN4924, siRNAs against the catalytic 
subunit of NAE (uba3) were used (Fig. 6C). 
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Thus, our data suggest that while the RPL11-mediated p53 activation by MLN4924 is 
cytoprotective, loss of RPL11 protects cells against MLN4924 by p53 independent 
mechanisms. 
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Discussion 
The NEDD8 conjugation pathway controls key cellular processes such as cell 
viability and cell cycle progression. The promising preclinical studies for inhibitors of 
NEDDylation have emphasized the importance of the NEDD8 pathway as a novel 
drug target. Therefore, elucidation of pathways that are controlled by NEDDylation is 
critical for our understanding of the mechanisms of action for these potential new 
chemotherapeutics. The MLN4924-induced activation of p53 is relevant to the 
cellular response to MLN4924 treatment, albeit the mechanism remains elusive. In 
this study, we show that MLN4924 activates the p53 tumour suppressor through the 
RP-Mdm2 pathway with characteristics of nucleolar stress. One of the pleiotropic 
effects of MLN4924 is to alter the morphology and to increase the size of the 
nucleolus. Similar effects on nucleolus size were observed in germline cells of 
MLN4924 treated C. elegans, which suggests a highly conserved role for protein 
NEDDylation to control the function of the nucleolus.  
Changes in nucleolar size and morphology are associated with changes in rates of 
proliferation. Indeed, nucleolar hypertrophy is linked to malignancy, as increase in 
Pol I activity and ribosome production is required to sustain higher rates of growth 51. 
Reduction in nucleolar size or fragmentation is linked with the action of 
chemotherapeutics such as ActD, which inhibit Pol I function and cause cell cycle 
arrest 24, 28. In the contrary, we found that MLN4924, a compound with anti-
proliferative effects, increases nucleolar size indicating that nucleolar hypertrophy 
may not always be associated to higher rates of cell growth.  
Quantitative proteomics showed that the MLN4924-induced morphological changes 
in the nucleolus are associated with a re-organisation of the nucleolar proteome that 
are of similar scale to the well-described nucleolar “stressor” ActD. However, a key 
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difference compared to ActD, is that MLN4924 does not affect rRNA 
production/processing. Interestingly, MLN4924 increases the nucleolar abundance of 
multiple members of the MCM family of DNA replication licensing factors, along 
with histone acetyltransferase complexes, which are essential for DNA replication 
licensing 52, 53 (supplementary information S3). Indeed, we found that the replication 
factor MCM2 is relocalised to the peri-nucleolar area upon MLN4924 treatment 
(supplementary information S5). Therefore, the increase in nucleolar size by 
MLN4924 may be associated to the increase in the abundance of replication 54 and 
acetylation factors either within the nucleolus or as nucleolar-associated proteins. 
Although the effects of MLN4924 and ActD on nucleolar function are different the 
downstream signaling events that lead to p53 activation are quite similar. Both 
compounds inhibit RPL11-NEDDylation and reduce the mobility of RPL11 in the 
nucleolus. Furthermore, the p53 activation induced by either compound depends on 
the interaction of RPL11/RPL5 with Mdm2, which is regarded as a key step in p53 
activation specifically upon nucleolar stress and not upon DNA damage 44. Therefore, 
despite the pleiotropic effects induced due to inhibition of CRL function, p53 
activation by MLN4924 depends strictly on the RP-Mdm2 module. We propose that 
MLN4924 causes “nucleolar stress” by affecting the nucleolar proteome rather than 
inhibiting nucleolar transcription. The downstream biological outcome is the 
signaling to cell cycle regulators such as p53 that depends on the RP-Mdm2 pathway. 
Interestingly, combination of MLN4924 with ActD provides an additive effect on p53 
stabilisation, indicating that these compounds act on the same signaling pathway 
(supplementary information S6). This further supports the notion that MLN4924 
activates p53 through nucleolar signaling, most likely downstream of PolI activity 
regulation and upstream of the RP-Mdm2 module. While our studies suggest that 
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NEDDylation of RPL11 is a target of MLN4924, we cannot exclude the possibility 
that the observed changes in the nucleolar proteome and resulting p53 activation is 
indirectly due to CRL inhibition. 
The nucleolus is viewed as a major hub for the detection of cellular stress, which 
elicits signaling events that control the activity of tumour suppressors and oncogenes 
24. The placticity and highly dynamic nature of the nucleolar proteome is a major 
determinant of decoding a stress signal to a signaling output 23. The changes in the 
nucleolar proteome upon stress conditions are directly linked to the regulation of key 
components of the cell cycle 23, 29. To our knowledge MLN4924 is the first example 
of a small compound that re-organises the nucleolar proteome and activates p53 with 
all the characteristics of “nucleolar stress” in the absence of inhibition of nucleolar 
transcription. The data suggest that targeting the nucleolar proteome may elicit the 
required signaling events to cell cycle regulators without affecting rRNA production 
and ribosome biosynthesis. This may be important as targetting Pol I activity is 
emerging as an attractive anti cancer approach 55, 56, 57. 
Intriguingly, neither MLN4924 nor ActD caused transcriptional activation of CEP-
1/p53 in C. elegans despite their clear effects on nucleolar morphology and size (Fig. 
3A, C, 5E). Previous studies in C.elegans showed that depletion of the nucleolar 
RNA-associated protein NOL-6 induces immunity against bacteria infection through 
activation of CEP-1/p53, suggesting that the nucleolus can signal to CEP-1/p53 under 
stress conditions 58. A homologue for Mdm2 has not been found in nematodes so it is 
possible that MLN4924 and ActD induced p53 activation depends strictly on the 
Mdm2 presence, whereas NOL-6 induced signaling depends on other E3-ligases or 
other mechanisms of CEP-1/p53 activity regulation (translational) 59. 
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While p53 activation by MLN4924 depends on RPL11, cell cycle analysis and 
survival assays show a differential role for p53 and RPL11 in the MLN4924 response. 
Our data are consistent with previous studies showing that the MLN4924 induced 
activation of p53 is cytoprotective 13. This is most likely due to the p53 induced G1 
arrest that prevents entry of cells in the S-phase where MLN4924 elicits toxicity. In 
contrary, RPL11 is required for the MLN4924-induced accumulation of cells in S-
phase and cytotoxicity. However, these effects are p53 independent, indicating that 
additional pathways controlled by RPL11 are involved in the MLN4924 biological 
response. For example, RPL11 controls the transcriptional activity of c-myc and 
cyclin expression 60,61,62. Indeed, loss of RPL11 was shown to suppress cell 
proliferation, in the absence of cell cycle arrest, independently of p53 62. The data also 
indicate that the rates of cell proliferation may be a critical determinant for the 
effectiveness of MLN4924 as potential chemotherapeutic.   
In summary, the present study shows that MLN4924 activates p53 through the RP-
Mdm2 pathway and suggests that targeting the nucleolus is, at least in part, a 
mechanism of action for inhibitors of NEDDylation.  
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Materials and Methods 
Gene expression 
RNA from MCF7 cells transfected with siRNAs and treated with ActD or MLN4924 
was isolated and used for cDNA synthesis. The cDNA was then used for quantitative 
real-time PCR (qRT-PCR) to monitor mdm2 expression. Primers for mdm2 (P2) 
promoter were previously described 63. Full details can be found in supplementary 
information.  
Isolation of His6-NEDDylated proteins, ribosome profiling 
Ni2+-pull downs and total cell extracts were prepared as described in 64, 65. Ribosome 
profiling was performed as described in 36.  
Detection of newly synthesised RNA and rRNA processing 
Transcription efficiency was monitored by 3H-uridine incorporation of newly 
synthesized RNAs as described 66. Briefly, H1299 cells were treated with ActD or 
MLN4924 and pulsed with 3H-uridine for 1hr at 37oC. RNA was isolated and 
subjected to agarose-formaldehyde gel electrophoresis. For monitoring rRNA 
processing, H1299 cells were treated as above for 8 or 15hrs and isolated total RNA 
was used for northern blotting with 32P-labelled probes to reveal either all 18S 
precursors (5’ITS1) or 28S and 5.8S (ITS2). Full details can be found in 
supplementary information. 
Microscopy 
FRAP experiments were performed in H1299 cells stably expressing RPL11-EGFP as 
described in 35. Details are included in supplementary information. For 
immunostaining in U2OS cells, samples were prepared and methods were used as 
described in 67. All primary antibodies were used at 1:100 dilution.  
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Flow cytometry 
MCF7 cells in 6 well plates were transfected with 5nM control, RPL11 and p53 
siRNAs as indicated. The total amount of siRNAs was normalised to 10nM with 
control siRNA. 48hrs post transfection cells were treated with either DMSO or with 
MLN4924 (0.5µM) for 24hrs. Cells were collected by trypsin, fixed with ethanol at 
4oC and labelled with propidium iodide for 30min. DNA content of 10,000 cells per 
condition was quantified on a FACS Calibur (Becton Dickinson) using Cell Quest 
acquisition software and employing pulse-width analysis to exclude doublets. Data 
were analysed using Flowjo software (Treestar Inc) and the Watson (pragmatic) 
model to determine cell cycle distribution.  
Treatments 
For each experiments of drug assay, 500 worms were treated at L4 larval stage in 
liquid culture of M9 medium complemented with cholesterol (5µg/ml) and HT115 
bacteria (4x105). MLN4924 was used at 100µM, Actinomycin D at 100nM and 
Doxorubicin at 100µM. Compounds were diluted in M9 solution before use. For UV 
response L4 worms were exposed at 100J/m2 and dissected 5 hours later. After 
treatment of MLN4924 or ActD, worms were dissected or put in trizol for qRT-PCR. 
Nucleoli volume quantification with Image J software 
Observations were performed using Zeiss Axioimager Z2. For each germline, 
pachytene stage was observed with 63x objective and stacks of all the thickness were 
obtained (0.5µm/stack) to see overall nucleus with Metamorph software. The same 
stack representing the nucleus (DAPI staining) and the nucleolus (Fibrillarin staining) 
was selected for further analysis. An average of 50 nuclei in human cells and 6 
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germlines-50 nuclei in C. elegans were used for each experiment. Full details can be 
found in supplementary information. 
Subcellular fractionation and proteomics. 
DMEM media depleted of arginine (R) and lysine (K) were supplemented with 10% 
dialysed FCS and either light (K0R0), medium (K4R6) or heavy (K8R10) labelled 
amino acids. U2OS cells were grown in different media and after 6 passages full 
incorporation was confirmed. 20x15cm dishes for each condition were grown till 80% 
confluency before treatment. Subcellular fractionation and isolation of nucleoli was 
performed as described in 20 and supplementary information.  
Survival assays 
MCF7 cells were seeded and transfected with 5nM of each of the siRNA pool in 24-
well plates (15000 cells/well). The total amount of siRNAs was normalised to 10nM 
with control siRNA. 24 hrs later, MLN4924 was added for the indicated periods 
before cell survival was measured with the CellTiter-Glo Luminescence assay from 
Promega according to manufacturer’s instructions. In each transfection (Fig. 6B), 
DMSO was added in control cells for 72 hrs.   
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Figure Legends 
 
Figure 1 
(A) H1299 cells were treated either with DMSO (control) or with MLN4924 (1µM) 
for 24hrs. Phase contrast micrographs were then taken and arrows indicate the 
position of nucleoli. (B) U2OS cells were treated with DMSO or MLN4924 (1µM, 
15hrs) before staining for nucleolin, fibrillarin or B23. (C) U2OS cells were treated as 
above for 24 hrs before cells were fixed and stained for fibrillarin to define the 
nucleolus and with DAPI to define the nucleus. The relative surface of the nucleoli 
was determined as described in supplementary information. (D) Quantitation of data 
represented as relative changes in surface size of the nucleolus (nucleolus/nucleus). 
(E) U2OS cells were treated with DMSO, ActD (5nM) or doxorubicin (1µM) for 
24hrs before fixing and staining for fibrillarin as in (A, C). 
Figure 2 
(A) C. elegans L4 adults were treated with DMSO or with MLN4924 (100µM for 
24hrs) or fed with NED-8 RNAi bacteria. The germlines were then dissected and 
stained for fibrillarin and DAPI as in Fig. 1. (B) The surface size of the nucleolus was 
determined as in Fig 1D. (C) In the experiment performed in A, animals were also 
treated with 100J/m2, or ActD (100nM) or doxorubicin (100µM) as described in 
materials and methods.  
Figure 3 
(A) MCF7 cells were treated with MLN4924 at the indicated doses for 24 hrs. Cells 
were lysed in 2xSDS buffer and extracts were analysed by western blotting. Equal 
loading was monitored with β-actin. (B) H1299 cells were transfected with His6-
NEDD8 (2µg), Flag-L11 (5µg). 24 hrs post-transfection cells were treated with 
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MLN4924 (1µM) for the indicated times before cells were harvested. NEDDylated 
proteins and total cell extracts were prepared as described in material and methods 
and analysed by western blotting with the appropriate antibodies. Signals for NEDD8-
L11 and total L11 were quantified using Image Gauge. Changes in absolute L11-
NEDDylation upon MLN4924 treatment were determined by the ratio of 
NEDDylated over total L11. (C) H1299 cells stably expressing RPL11-EGFP were 
treated for 4hrs with DMSO, ActD (5nM) or MLN4924 (1µM) before the FRAP 
experiment. The half-life of recovery (bottom left) and the mobile fraction (bottom 
right) were calculated as described in materials and methods. 
Figure 4 
(A) MCF7 cells were transfected with either control or RPL11 siRNAs in duplicates, 
before treated with MLN4924 (1µM, left panel) or ActD (5nM, right panel) as 
indicated. Cell extracts and western blot analysis was performed as in Fig.1. (B) 
Experiment performed as in (A) for the indicated time points and mRNA was isolated 
as described in Materials and Methods. Expression of the mdm2 gene was monitored 
by qPCR. Expression of actin was used to normalise the values. Data are represented 
as mean values +/- standard deviations from 3 independent experiments. (C) 
Experiment performed as in (A) with individual siRNAs against different parts of 
RPL11 sequence and treating cells with MLN4924 as indicated. (D) Wild type MEFs 
or MEFs expressing the Mdm2C305F mutant were treated with ActD (5nM) or 
MLN4924 (1µM) as indicated. Cell extracts were analysed by western blotting for the 
indicated proteins (E) C. elegans L4 adults were treated as indicated before 
expression of egl-1 was determined by qPCR. For UV, expression was determined 
5hrs post treatment and 24hrs post chemical treatment. 
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Figure 5 
(A) Strategy for SILAC labelling in U2OS cells and proteomic analysis of nucleoli. 
(B) Profile of nucleolar proteins affected by MLN4924 or ActD. (C) Bioinformatic 
analysis using Panther software illustrating biological processes affected by 
MLN4924 and ActD. (D) Proteins affected both by MLN4924 and ActD. (E) H1299 
cells were pre-treated with DMSO (5hrs), ActD (5nM) or MLN4924 (1µM) as 
indicated in duplicates and one set of cells was used for labelling for 1hr with 3H-
uridine and monitoring of rRNA production. EtBr staining was used to monitor 
loading of total RNA. The other set of cells was used for lysis in 2xSDS lysis buffer 
and western blot analysis (low panel). (F) H1299 cells were treated as above for 8 or 
15 hrs.  rRNA processing was monitored with the indicated probes as described in 
methods. (G) H1299 cells were treated as above for 15hrs. Cells were harvested and 
extracts were used for ribosome profiling as described in methods. 
Figure 6 
MCF7 cells were transfected with either control, RPL11 and p53 siRNAs as 
indicated. 48hrs post-transfection cells were treated with DMSO or with MLN4924 
(0.5µM) for 24hrs before cell cycle analysis. Histograms show the cell cycle profiles 
and % of cell populations in different phases. (B) MCF7 cells were transfected with 
the indicated siRNAs and 24hrs later cells were exposed to MLN4924 (1µM) for 24, 
48 or 72hrs. For each siRNA experiment, survival was normalised against the control 
treated (DMSO) cells, represented as 100%. (C) To mimic the experiment performed 
in B using MLN4924, siRNA against the catalytic subunit of NAE was used in 
combination with RPL11 and p53 siRNAs as indicated. Cell survival was measured 
72hrs later and values are presented as percentage changes over the control siRNA 
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transfected cells. For experiments in B and C, data presented the average of 3 
independent experiments +/- standard deviations. 
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The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates 
p53 through the ribosomal-Mdm2 pathway 
Aymeric Bailly, Aurelien Perrin, Lara Bou Malhab, Emmanuelle Pion, Mark Larance, 
Manjula Nagala, Peter Smith, Marie-Françoise O'Donohue, Pierre-Emmanuel 
Gleizes, Joost Zomerdijk, Angus I. Lamond and Dimitris P. Xirodimas 
 Supplementary information 
Materials and Methods 
Antibodies and chemicals 
DO-1 mouse monoclonal antibody was used for p53 detection, rabbit anti-L11 was a 
gift from Karen Vousden, mouse anti-!-actin (Oncogene Research Products), mouse 
anti-Cullin-1 (Zymed), mouse anti-FLAG, mouse anti-aTubulin (Sigma-Aldrich), 
rabbit anti-Cullin-4A, rabbit anti-nucleolin, rabbit anti-RPL5, mouse anti-fibrillarin 
mAb (Abcam), rabbit anti-B23 (Sigma), rabbit anti-MCM2, rabbit Calnexin (Cell 
Signaling), rabbit anti-p21 (Santa Cruz). Actinomycin D, Doxorubicin and G418 were 
purchased from Sigma-Aldrich, MLN4924 from Active Biochem.  The BCA protein 
assay kit was purchased from Pierce. Triscarboxyethylphosphine (TCEP) (Bond-
breaker neutral pH solution) was from Pierce (Rockford, IL). Trypsin was from 
Promega (Madison, WI). Oasis HLB 96-well m-elution 96-well plates were from 
Waters (Rockford, CA). The Pepmap C18 columns and trapping cartridges were from 
Dionex (Sunnyvale, CA). Complete protease inhibitor cocktail tablets and PhosStop 
phosphatase inhibitor tablets were from Roche (Indianapolis, IN). Lavapep assay 
reagents were from GelCompany (San Francisco, CA). All other materials were 
obtained from Sigma-Aldrich (St. Louis, MO). All siRNAs were purchased from 
Dharmacon as ON-TARGETplus pools or individual duplexes. The control siRNA is 
a non-target pool. 
 
 
Cell culture and transfections 
Cell lines were grown in Dulbecco’s modified Eagle’s medium except H1299 grown 
in RPMI, all supplemented with 10% fetal calf serum. Transfections in H1299 cells 
were performed with calcium phosphate in 10cm dishes. 5nM of siRNAs were 
transfected in cells seeded in 6-well dishes with lipofectamine RNAiMAX according 
to manufacturer’s instructions. Cells were harvested 36-48hrs post transfections. 
H1299 cells stably expressing RPL11-EGFP were selected with 0.5mg/ml of G418. 
Gene expression 
48hrs post transfection with siRNAs, MCF7 cells were treated with ActD or  
MLN4924. Promega SV Total RNA Isolation system was used to isolate total RNA. 
cDNA was made using the Invitrogen SuperScript® III First- Strand Synthesis 
SuperMix for qRT-PCR  with 300ng of RNA. The cDNA was diluted with H2O 20x 
and 2µl were used in a 12µl reaction. Quantitative real-time PCR was carried out in 
an ABI 7500 system using ABI PCR master mix according to the manufacture’s 
instructions. Gravid adult worms were collected from the plates and wash three times 
to remove bacteria with PBS before introduction in Trizol and frozen at -80°C. Total 
RNA were extract by Trizol/chloroform and follow by RNeasy® Kit (Qiagen) and 
cDNA synthesis performed on 300ng of RNA with QuantiTech® Reverse 
Transcription Kit (Qiagen). qRT-PCR reactions were performed in triplicates, and 
cDNA was diluted in MesaGreen qPCR Master Mix (Eurogentec) with specific 
primers. The means measured for levels of transcript of interest (egl-1) were 
normalised with internal level of transcript control (tubulin tbg-1). For data analysis, 
maximum quantitative point method was applied and induction was calculated with 
the equation: 
Fold Induction= 2^((!Cp(cDNAegl-1-cDNAtbg-)control)-( !Cp(cDNAegl-1-cDNAtbg-)treated)) 
Northern blot analysis of pre-rRNA  
Control cells or cells treated for 8hrs or 15hrs with ActD or MLN4924 were collected, 
rinsed with PBS and centrifuged. Total RNAs from 7 ! 106 cells were then extracted 
with Trizol reagent, and further purified with phenol/chloroform/isoamyl alcohol 
(25:24:1) and chloroform extractions. After alcohol precipitation of the aqueous phase 
and extensive washings with 70% ethanol, RNA pellets were dissolved in formamid, 
denatured at 70°C for 10 min, and quantified using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific). Pre-RNAs (3"g total RNAs/well) were separated on a 
1.1% agarose gel prepared with Tri/Tri buffer (30mM tri-ethanolamine, 30mM 
tricine, pH 7.9) containing 1.2% formaldehyde, and run in Tri/Tri buffer at 140 volts. 
RNAs were then transferred to a Hybond N+ nylon membrane (GE Healthcare, Orsay, 
France) and fixed by UV-cross-linking. The membrane was pre-hybridized for 1hr at 
45°C (6! SSC, 5! Denhardt's solution, 0.5% SDS, 0.9"g/ml tRNA). The 32P-labelled 
oligodeoxynucleotide probe was then incubated overnight at 45°C. The probes used 
were: 5’ITS1 (5’-cctcgccctccgggctccgttaatgatc-3’), that reveals all the 18S precursors; 
a mixture of ITS2b (5’-ctgcgagggaacccccagccgcgca-3’) and ITS2d/e (5’-
gcgcgacggcggacgacaccgcggcgtc-3’), that reveal 5.8S and 28S precursors; 18S (5’-
tttacttcctctagatagtcaagttcgacc-3’); 28S (5’-cccgttcccttggctgtggtttcgctagata-3’). After 
hybridization, the membrane was washed twice for 10min at room temperature in 2! 
SSC, SDS 0.1%, and once in 1! SSC, SDS 0.1%. Labelled RNA signals were 
acquired with a Typhoon Trio Imager (GE Healthcare) and quantified with the 
ImageGauge software. 
 
RNAi bacterial growth conditions (C. elegans)  
E. coli HT115 RNAi bacteria were grown in M9 minimal medium, prepared by 
mixing 100ml of 10x M9 salts (420mM disodium phosphate, 240 mM 
monopotassium phosphate, 90mM sodium chloride, 190mM ammonium chloride) and 
deionized water and autoclaved (120 °C for 20 min). 1ml of M9 bacterial 1X is 
completed by 5µl of 40% (wt/vol) glucose, 1µl of 1M MgSO4, 1µl of 1% (wt/vol) 
thiamine and 1µl of 100mg/ml ampicillin. A single bacteria colony streaked on LB 
plate is used to start the culture at 37°C under agitation until OD600=1. Bacteria 
culture is seeded on NGM plates. Worms are placed on NGM plates seeded with 
RNAi bacteria at late L4 stage during 24 hours and dissected. 
Nucleoli size quantification with Image J software 
Images were imported into Image J (http://rsb.info.nih.gov/ij/) as tiff files. (A, B) The 
first step was to adjust the minimal fluorescence threshold representative for DAPI 
and FIB-1 staining to define the perimeter of nucleus and nucleolus to exclude 
background and determine the area. (Command “Image>Adjust>Threshold”) (C, D). 
The free hand tool was used and a circle was drawn around the nuclei to measure 
(Command “Measure”) the number of pixels included between the minimal and 
maximal threshold analysed by software. In the circle only the higher level of 
intensity established by the minimal threshold was included in the measurement, 
which is independent of labelling intensity. Measurements were analysed by excel to 
compare the size of the nucleus and the nucleolus. The relative size of the nucleolus 
was determined by dividing the nucleolar/nuclear intensity and presented as % 
change.  
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Detection of newly synthesised RNA 
Transcription efficiency was monitored by 3H-uridine incorporation of newly 
synthesized RNAs as previously described 1. H1299 cells were seeded in 6 well plates 
and were either DMSO, ActD or MLN4924 treated. Cells were pulsed with 3!Ci/ml 
of 3H-uridine for 1 hr at 37oC. Cells were washed once with PBS and total RNA was 
isolated using RNAeasy kit (Qiagen) following manufacturer’s instructions. 4mg of 
RNA was subjected to agarose-formaldehyde gel electrophoresis. The EtBr-stained 
gel was photographed and electroblotted onto GE Nylon, Positively Charged Transfer 
Membrane. The 3H-labeled RNA was UV-irradiated, sprayed with tritium enhancer 
(Perkin Elmer) and exposed to Kodak X-ray film for 3 days.  
Staining 
Worms were dissected on poly lysine coated slides in PBS. Germlines were then fixed 
in 1.8% formaldehyde for 5 min at room temperature followed by freeze cracking in 
liquid nitrogen. Post-fixation was done in a 1:1 mixture of methanol:acetone at 
"20°C, followed by permeabilization with PBS+ 1% Triton X-100 (three times for 10 
min, room temperature). Samples were blocked with Image-iT FX signal enhancer 
(Invitrogen) for 20 min, followed by 15 min of incubation in PBS+ 0.1% Tween 
20+1%BSA (PBSTB). Primary antibodies were diluted in PBSTB at 4°C overnight in 
a humid chamber. Samples were washed three times for 10 min in PBS + 0.1% 
Tween 20 (PBST). Secondary antibodies were incubated for 2h at room temperature 
diluted in PBSTB supplemented with 1µg/µl DAPI. After washing three times for 10 
min in PBST, the samples were mounted in Vectashield mounting medium (Vector 
laboratories). Pictures were acquired with a Zeiss Axioimager Z2 using metamorph 
software. Anti-fibrillarin antibody was used at 500x dilution and the secondary Alexa 
goat-anti-mouse 488, combined with DAPI at 500x dilution. 
Fluorescence Recovery After Photobleaching (FRAP) 
H1299 cells stably expressing RPL11-EGFP were seeded in glass-bottom dishes 
(WILCO, Intracel) and treated with ActD and MLN4924 for 4hrs as indicated. Cells 
were placed in a temperature-controlled chamber at 37 C (Solent Scientific, UK). 
Nucleoli were photobleached for 0.1 sec with a 488 nm, 20 mW laser at 10% power 
focussed through a 60x oil immersion objective. This provided approximately 60% 
decrease in EGFP signal. Data were acquired from 20 randomly selected nucleoli. For 
each nucleolus, 32 images were captured within 15 sec and data were analysed with 
SoftWorx (Applied Precision, Seattle).  
Subcellular fractionation and proteomics 
Denaturing Gel Filtration Chromatography, Trypsin Digestion and Peptide Clean-up 
Using a Dionex Ultimate 3000 HPLC system, subcellular fractions in 6M guanidine-
HCl were injected (20µl per injection – 40µg protein) onto a mAbPacSEC column 
from Dionex equilibrated with 6M Urea, 2M Thiourea, 0.1M Tris-HCl pH 7.0 
flowing at a rate of 0.2ml per minute and collecting 32x50 µl fractions in a deep-well 
low protein binding 96-well plate (Eppendorf). Three volumes of 0.1M Tris-HCl pH 
8.0, 1mM CaCl2 was added to each fraction to dilute the urea, trypsin was 
subsequently added at a ratio of 1:50. The plate was sealed with a rubber mat, 
vortexed and incubated overnight at 37oC. Trifluoroacetic acid was added to 1% final 
concentration and peptides purified using an Oasis HLB 96-well m-elution 96-well 
plate. Peptides were eluted in 100µl of acetonitrile and speedivaced to dryness prior to 
resuspension in 5% formic acid. Peptide concentration was determined using a 
Lavapep assay after 500-fold dilution of peptide samples.  
 
  
 LC-MS/MS and Maxquant Analysis  
Using a Dionex Ultimate 3000 nanoHPLC system, 1µg of peptides in 5% formic acid 
were injected onto an Acclaim PepMap C18 nano-trap column (Dionex). After 
washing with 2% acetonitrile 0.1% formic acid peptides were resolved on a 150mm x 
75µm Acclaim PepMap C18 reverse phase analytical column over a 100min organic 
gradient with a flow rate of 250nL/min. Peptides were ionised by nano-electrospray 
ionisation at 1.2kV using a stainless steel emitter with an internal diameter of 0.005 
mm (Proxeon, Denmark). Tandem mass spectrometry analysis was carried out on a 
LTQ-Velos Orbitrap mass spectrometer Thermo Scientific (San Jose, CA).  
The data dependent acquisition method used was the FT10 protocol as described 
previously 2. Data were processed, searched and quantified using the Maxquant 
software version 1.1.1.14 package as described previously 3 using the default settings 
using the human Swissprot and Tremble database version. The settings used for the 
Maxquant analysis were: 2 missed cleavages allowed; enzyme was Trypsin cleaving 
after arginine and lysine; variable modifications were methionine oxidation; 
deamidation of glutamine or asparagine; peptide N-terminal pyro-glutamic acid; 
protein N-terminal acetylation; a mass tolerance of 7ppm was used for precursor ions 
and a tolerance of 0.5Da was used for fragment ions. Using the default Maxquant 
settings a maximum false positive rate of 1% is allowed for both peptide and protein 
identification this is used as a cut-off score for accepting individual spectra as well as 
whole proteins in the combined search and quantitation output. This threshold has 
previously been shown to be a rigorous method of identifying true positive matches 3. 
Protein quantitation data was always derived from two or more peptides per protein.  
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Western blot analysis of different fractions during nucleoli isolation.  
Cy: Cytoplasm, S2 and S3: nuclear fractions, No:Nucleoli 
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‘Ingenuity pathways analysis’ (www.ingenuity.com) was used to create networks for proteins  
affected by MLN4924 (A, B) and ActD (C, next page). The colour indicates the effect of each  
treatment on the nucleolar abundance for each protein (red: increase, green: decrease). The networks  
with the highest scores are presented. 
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Peri-Nucleolus 
Peri-nucleolar relocalisation of MCM2 upon MLN4924 treatment 
(A) U2OS cells were treated with either DMSO or with MLN4924 (1µM) for 24h before cells were 
fixed and stained for MCM2, Nucleolin and DAPI. (B) Nucleolin staining was used to define 
nucleoli and fluorescence intensity for nucleolin and MCM2 was measured across the drawn line 
indicated in A. To quantify the localisation of MCM2 around the nucleoli after MLN4924 treatment, 
the acquired images were analysed using the Image J software (http://rsb.info.nih.gov/ij/) as 
described in 4. For each channel (staining) the plot profile was determined (Command 
“Analyse>Plot profile”) and measurements were  exported to excel to make the “Plot profile” graph. 
The two arrows (blue) show the peri-nucleolar relocalisation of MCM2 after MLN4924 treatment.  
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Combination of MLN4924 with ActD produces an additive effect on p53 stabilisation 
MCF7 cells were treated with the indicated doses of MLN4924, ActD or with DMSO for  
15 hrs. Cells were lysed in 2xSDS and extracts were analysed by western blotting (top panel). The  
asterisks indicate the bands used for p53 quantitation (lower panel) with Image J.     
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Nucleolar Isolation Protocol
We recommend that you first download and read this page as a . Using that as your 
guide, you can then follow the protocol below and view a Quicktime movie demonstrating the 
key steps. We have also included higher resolution stills which provide close-ups of certain 
steps of the protocol.
PDF file
Special Feature: Complete nucleolar isolation protocol in one Quicktime movie
Click  to view at high resolution (25.8 Mb)here
Warning: this can take a long time to load, depending on the 
speed of your connection. Please be patient!
 
Click  to view at low resolution (9.2 Mb)here
This movie loads more quickly than the high resolution 
version, but some details are difficult to resolve. 
The movie stars , who optimized the original protocol.Dr. Yun Wah Lam
(All solutions are supplemented with Complete Protease inhibitor tablet (Roche, Cat no: 1-873-
580) at the final concentration of 1 tablet/50ml):
Buffers and solutions
 10 mM Hepes, pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT
: 0.25 M Sucrose, 10 mM MgCl2 
 0.35 M Sucrose, 0.5 mM MgCl2 
 0.88 M Sucrose, 0.5 mM MgCl2 
PBS
Buffer A:
S1 solution
S2 solution:
S3 solution:
See “Notes” below on making stock sucrose solution.
Procedure
Note: Nucleoli were prepared from HeLa cells using a variation on a method described by Muramatsu and co-
workers in 1963 (Muramatsu M, Smetana, K., and Busch, H.: Quantitative aspects of isolation of nucleoli of the Walker 
carcinosarcoma and liver of the rat. Cancer Res. 1963; 25:693-697).
1. Seed HeLa cells (ATCC number: CCL-2) on to 10x14 cm Petri dishes and culture at 37oC in 
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) containing 4mM L-glutamate, 4.5 mg/ml 
glucose and 0.11 mg/ml sodium pyruvate (Invitrogen UK, Cat no: 41966-029), supplemented 
with 100 U/ml Penicilin and 100 µg/ml Streptomycin (1% v/v Penicilin/Streptomycin solution, 
Invitrogen UK, Cat no: 15140-122) until >90% confluence (approx. 107 cells per dish). This 
number of HeLa cells consistently provides nucleoli with excellent yield and purity. It is 
possible to scale down the preparation, although purity of the isolated nucleoli may suffer. 
Make sure you monitor every step using a phase contrast microscope (see below). 1 hour 
before nucleolar isolation, replace with fresh, pre-warmed medium. 
2. Harvest cells by trpysinization. Rinse each dish 3X with pre-warmed PBS, and on removal of 
the last rinse, add 2 ml of trypsin-EDTA solution (Invitrogen UK, Cat no: 25300-054) per dish. 
Swirl the dishes to make sure the trypsin-EDTA is evenly distributed, and return the dishes to 
the incubator for about 5 min. Check under a phase contrast microscope that all the cells are 
detached. Prolong incubation if needed. Add into each dish 8 ml of pre-warmed medium, 
pipette up and down so that all the cells are collected as a single-cell suspension. Pool all the 
harvested cells into 2x 50ml Falcon tubes. For some strains of HeLa cells, it is also possible to 
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harvest the cells by scraping them in 5 ml ice-cooled PBS per dish. Since scraping may lead to 
impure nucleolar preparation in some HeLa strains, it is not recommended as the method of 
first choice.
3. Wash 3 X with ice-cold PBS at 218 g (1000 rpm, Beckman GS-6 centrifuge, GH-3.8 rotor) at 
4oC.
4. After the final PBS wash, resuspend the cells in 5ml of Buffer A and incubate the cells on ice 
for 5 min. Put a small drop of the cell suspension on a glass slide and check under a phase 
contrast microscope, such as a Zeiss Axiovert 25, using a 20X objective. The cells should be 
swollen, but not burst (Fig 1). Nucleoli of cultured mammalian cells disassemble at 37oC in 
hypotonic conditions (Zatsepina et al, 1997). It is therefore imperative to keep the cell 
suspension on ice during this step.
Figure 1: HeLa cells after step 4. Note the swollen cytoplasm and prominent 
nucleoli. Bar: 10µm.
5. Transfer the cell suspension to a pre-cooled 7 ml Dounce tissue homogenizer (Wheaton 
Scientific Product Cat no: 357542). Homogenize 10 times using a tight pestle (“A” 
specification: 0.0010" - 0.0030" clearance), while keeping the homogenizer on ice. The number 
of strokes needed depends on the cell type used (see “Notes”). It is therefore necessary to 
check the homogenized cells under a phase contrast microscope after every 10 strokes. Stop 
when >90% of the cells are burst, leaving intact nuclei, with various amounts of cytoplasmic 
material attached. In most cases, the presence of this cytoplasmic contamination does not 
affect the final purity of the isolated nucleoli (Figure 2).
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6. Centrifuge the homogenized cells at 218g (1000 rpm, Beckman GS-6 centrifuge, GH-3.8 
rotor) for 5 min at 4°C. The pellet contains enriched, but not highly pure, nuclei.
7. Resuspend the pellet with 3 ml S1 solution (Figure 3). The pellet should be resuspended 
readily by pipetting up and down. A pellet that cannot be resuspended contains lysed nuclei 
and should be discarded. Layer the resuspended pellet over 3 ml of S2 solution. Take care to 
keep the two layers cleanly separated. Centrifuge at 1430g (2500 rpm, Beckman GS-6 
centrifuge, GH-3.8 rotor) for 5 min at 4°C. This step results in a cleaner nuclear pellet (Figure 
3). Resuspend the pellet with 3 ml of S2 solution by pipetting up and down. 
Figure 3. Step 7 of the procedure. Note the clear boundary between S1 and S2 layers before 
centrifugation. Insets show the DIC images of the supernatant and pellet. Note the prominent 
nucleoli inside the nuclei in the pellet. Bars: 10µm.
8. Sonicate the nuclear suspension for 6 x 10 second bursts (with 10 second intervals between 
each burst) using a Misonix XL 2020 sonicator fitted with a microtip probe and set at power 
setting 5 (Figure 4 Left). Check the sonicated nuclei under a phase contrast microscope. There 
should be virtually no intact cells and the nucleoli should be readily observed as dense, 
refractile bodies (Figure 4 right). The optimal sonication time depends on the cell type used. If 
you attempt to isolate nucleoli from a cell type from the first time, it is necessary to check the 
sonicated material under a microscope after every 10 seconds of sonication. Over-sonication 
leads to destruction of nucleoli.
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Figure 4. Left. Setup for sonication. Right. DIC image of sonicated nuclei. Note the presence of 
prominent nucleoli. Bar: 10µm.
9. Layer the sonicated sample over 3 ml of S3 solution and centrifuge at 3000g (3500 rpm, 
Beckman GS-6 centrifuge, GH-3.8 rotor) for 10 min at 4°C (Figure 5). The pellet contains the 
nucleoli, whilst the supernatant can be retained as the “nucleoplasmic fraction” (Figure 5).
Figure 5: Step 9 of the procedure. Note the clear boundary between S2 and S3 layers before and 
after centrifugation. The pellet should be small but visible. Insets show DIC images of the 
supernatant and pellet. The pellet should contain purified nucleoli. Bars: Left inset: 10µm, right 
inset: 20µm.
10. Resuspend the nucleoli with 0.5 ml of S2 solution, followed by centrifugation at 1430 (2500 
rpm, Beckman GS-6 centrifuge, GH-3.8 rotor) for 5 min at 4°C. The pellet contains highly 
purified nucleoli. Check under a phase contrast microscope to ensure this preparation contains 
only highly purified nucleoli without any other material (Fig 5). The nucleoli can be 
resuspended in 0.5ml of S2 solution and stored at –80oC. 
Notes
(1) Making 2.55M sucrose stock
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Here is a protocol for preparing a sucrose stock solution (Cline and Ryel,l 1971) suitable for 
the nucleolar isolation protocol. The resulting solution is 2.55M, or 66% by weight. Its density 
is 1.3224g/cm3 at 20oC, and refractive index is1.4558. The stock solution is stable indefinitely 
at 4oC. This procedure can be carried out at RT. There is no need to heat up the solution to 
help dissolving the sucrose. Heating up an incompletely dissolved sucrose solution can lead to 
charring of sucrose and affect the quality of the sucrose solution.
1. Weigh out 1710 g sucrose (BDH). Keep it aside in a clean container.
2. Put exactly 900ml water and a magnetic bar in a 5 litre beaker. Put the beaker on a stirrer and start stirring.
3. Add 1/3 of the sucrose into the beaker. Make sure the magnetic bar is rotating freely. Stir for 1 hour.
4. Add another 1/3 of the sucrose into the solution. Again make sure the rotation of the stir bar is not impaired. Stir for 
another 1 hour.
5. Add the remaining sucrose. Stir for another 1 hour, or until all the sucrose has gone into solution. The final volume should 
be exactly 2 litres.
We use a Misonix 2020 sonicator fitted with a microtip at power setting 5. To ensure 
reproducible soncation these points should be followed:
(2) Sonication
- It is necessary to tune the sonicator every time after you change the probe. Follow the manufacturer’s manual for the 
tuning procedure.
- Sonication produces intense and localized heat in your solution. If you are concerned about the heating, the correct way to 
reduce heating is to shorten the sonication time and to increase the intermission between bursts. Keeping the tube on ice or 
performing the sonication in the cold room is helpful, but is not the most effective way of heat control.
- If the probe is too close to the liquid surface, it produces a foam and reduces the efficiency of sonication. Make sure the 
probe is well submerged in the solution, about 5mm above the bottom of the tube. Do not, however, touch the bottom or the 
wall of the tube with the probe.
- Sonicator probe that has been used repeatedly develops pits on its end. The sonication efficiency gradually decreases as 
time goes on. Therefore, the sonication time reecommended here can only be used as guideline. Always monitor the outcome 
of sonication using a phase contrast microscope. You may need to adjust the sonication time to maintain the efficiency 
especially if the probe is getting old. Change the probe when the efficiency is noticeably down.
- To immunolabel the purified nucleoli, spot about 5 µl of the nucleolar suspension on to a 
polylysine-coated slide (BDH Cat no: 406/0178/00), and air dry the spot. Rehydrate the slide 
in PBS for 5 min before carrying out a standard immunostaining procedure.
- To separate nucleolar proteins on a gel, either resuspend directly in Laemmli SDS sample 
buffer or in your preferred buffer. The high concentration of nucleic acid in the isolated 
nucleoli makes the lysed sample very viscous. The sample can be clarified by passing through 
a QIAshredder spin column (Qiagen Cat no: 79654). Nucleoli can also be extracted with RIPA 
buffer (150 mM NaCl,1% NP40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, COMPLETE 
protease inhibitor cocktail). Immunoprecipitations can be performed from nucleolar lysates 
prepared in RIPA buffer.
(3) Analysis of the isolated nucleoli
The above protocol can readily be adapted to other cell types. Apart from HeLa cells, we have 
used this protocol, with minor modifications, to isolated nucleoli from MCF-7 (human breast 
epithelium), WI-38 (human fibroblast), IMR-32 (human neuroblastoma), HL60 (human 
promyelocytic leukemia) and plant Arabidopsis thalina cells. When adapting the protocol to a 
different cell type, make sure you control each step by carefully checking the products after 
each step under a phase contrast microscope. For example, different cell types may require a 
different homogenization (step 4) and/or sonication strength (step 7). The concentration of 
MgCl2 also appears crucial to the purity of the isolated nucleoli. If the isolated nucleoli are not 
pure enough, try lowering the concentration of MgCl2 in the S2 and S3 solutions. If the yield is 
poor, or if the nucleoli look fragmented, use more MgCl2. 
(4) Adapting nucleolar isolation protocol to use with other cell types
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